Currently, the most common method of diagnosing prostate cancer typically follows serum prostate-specific antigen (PSA) testing or digital rectal examination (DRE), and succeeded by transrectal ultrasound (TRUS)-guided prostate biopsy. This evidence concerns the gene KLK3 and prostate cancer.